ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2500-Wollongong-Cancer-Care-Wollongong
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
17
trial(s) found.
NCT07772934
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2a Open-label Clinical Trial Evaluating VBC117, an EGFR and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors (
VBC117-01-01
)
bispecific-EGFR/CDH17 antibody-drug conjugate
oncolytic herpes simplex virus
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT07723482
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2 Study of ML-016 in Participants With Advanced Cancer With Lung and/or Liver Involvement (
BP-ML-016-01
)
Doxorubicin
anthracycline
cancer therapy
cytotoxic chemotherapy
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
2500 - Wollongong - Cancer Care Wollongong
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT07694765
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors (
LM364-01-101
)
anti-NECTIN4 antibody-drug conjugate
Cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07112222
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors (
LM350-01-101
)
anti-CDH17 antibody-drug conjugate
Cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06923761
Advanced
Phase 1 / Phase 2
Recruiting
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies (
EMITT-1
)
ERAP1 inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Cancer Care Wollongong
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06868199
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (
LM168-01-101
)
anti-PD-1 monoclonal antibody
unknown drug class
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
WA
6009 - Nedlands - One Clinical Research
NCT06801834
Advanced
Phase 3
Recruiting
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) (
EVOKE-SCLC-04
)
anti-Trop2 antibody-drug conjugate
Small-cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06751329
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
bispecific-ERBB3/MUC1 antibody-drug conjugate
Colorectal adenocarcinoma
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Cancer Care Wollongong
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
2830 - Dubbo - Dubbo Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT06697301
Advanced
Phase 2 / Phase 3
Recruiting
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006) (
EIK1001-006
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Melanoma
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06656390
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors (
ALK201-01
)
anti-FGFR2b antibody-drug conjugate
Cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Cancer Care Wollongong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
Breast cancer
Epithelial Ovarian Cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NCT05458219
Advanced
Phase 1
Recruiting
A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI343A101
)
anti-CLDN18.2 antibody-drug conjugate
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Cancer Care Wollongong
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
NCT04613596
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (
CA239-0009
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Cancer Care Wollongong
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Not yet recruiting (3)
Recruitment Country and State
NSW (17)
QLD (12)
VIC (9)
SA (9)
WA (5)
NZ (3)
ACT (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (9)
Phase 2 / Phase 3 (3)
Phase 3 (3)
Trial Type
Advanced (15)
Haem (2)
Cancer Therapy Class
PD-1/PD-L1
47%
PD-1
41%
Trop2
12%
PD-L1
12%
VEGFA
12%
Nectin4
6%
CDH17
6%
ERAP1
6%
TLR7/TLR8
6%
FGFR2
6%
FGFR2b
6%
STING
6%
CDK2
6%
CDK4
6%
CDK6
6%
ER
6%
oestrogen axis
6%
cereblon
6%
proteasome
6%
CLDN18.2
6%
KRAS
6%
Facility
2500 - Wollongong - Cancer Care Wollongong (17)
2109 - North Ryde - Macquarie University Hospital (5)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
5042 - Bedford Park - Flinders Medical Centre (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
5000 - Adelaide - Cancer Research SA (2)
2170 - Liverpool - Liverpool Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4870 - Cairns - Cairns Base Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3168 - Clayton - Monash Medical Centre (2)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2228 - Miranda - Southside Cancer Care Centre (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
6009 - Nedlands - One Clinical Research (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
2830 - Dubbo - Dubbo Base Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
4215 - Southport - Tasman Oncology (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Respiratory tract cancer
Thoracic cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Non-small cell lung cancer
Melanoma
Breast adenocarcinoma
Breast cancer
Gynaecological cancer
Haematological malignancy
Triple-negative breast cancer
Colorectal adenocarcinoma
Colorectal cancer
Exocrine pancreatic cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
B-cell lymphoma
B-cell malignancy
Bladder cancer
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Skin cancer
Urogenital cancer
Uveal melanoma
Viral-related cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Peritoneal cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy